VANCOUVER, March 14, 2016 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today announced that its oncology drug candidate PNT2258 has been granted Orphan Drug…